Advertisement

Topics

FDA halts trial after first CAR T-associated patient death

06:59 EDT 6 Sep 2017 | Pharmafile

French clinical-stage biopharma firm Cellectis has received an order from the FDA to halt its study of CAR T therapy UCART123 after a 78-year old patient died as a result of a toxic reaction to the treatment.

read more

Original Article: FDA halts trial after first CAR T-associated patient death

NEXT ARTICLE

More From BioPortfolio on "FDA halts trial after first CAR T-associated patient death"

Quick Search
Advertisement